Hi Morpheus, I agree with your commercial question of why RHY has not vigourously pursued sales in the EU based on the earlier announcements. They appointed a medical firm Link in the UK following the May approval. So either the earlier approvals were not complete, or you are right - why hasn't mgt commenced selling in the UK since 30 Nov 21?
The ASX query on insider trading is mportant to be resolved, but the bigger question is the question yoiu have raised from a shareholder viewpoint. Be interesting to hear RHY's response to this.
Hi Morpheus, I agree with your commercial question of why RHY...
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.002(2.78%) |
Mkt cap ! $17.40M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.0¢ | 6.9¢ | $1.212K | 17.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37250 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.002 ( 1.43 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 6.9¢ | 34578 | ||
| Last updated 15.27pm 06/06/2024 ? | |||||
| RHY (ASX) Chart |